Indivior PLC (LON: INDV) today announced that Shaun Thaxter, Chief Executive Officer, and Mark Crossley, Chief Financial Officer, will participate in Jefferies 2019 Healthcare Conference taking place in New York ...

Indivior PLC (LON: INDV) on Saturday announced data from two new studies: the first provides insights into dosing of once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for subcutaneous use (CIII), for the ...

Indivior PLC (LON: INDV) today announced the launch of once-monthly PERSERISTM (risperidone) for extended-release injectable suspension in the United States. PERSERIS is approved by the U.S. Food and Drug Administration ...

Indivior PLC (LON: INDV) today announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The ...

Indivior PLC (LON: INDV) today announced that data from its pivotal phase 3 clinical trial evaluating the efficacy, safety and tolerability of SUBLOCADETM (buprenorphine extended-release) injection for subcutaneous use (CIII), ...

Indivior PLC using EPIC/TICKER code (LON:INDV) had its stock rating noted as ‘Downgrades’ with the recommendation being set at ‘HOLD’ today by analysts at Jefferies International. Indivior PLC are listed ...

Indivior PLC (LON:INDV), today announced FY 2018 Adjusted Financial Results. Period to December 31st   Q4 2018 $m Q4 2017 $m % ∆ Actual FX % ∆ Constant FX FY ...

Indivior PLC (LON: INDV)  today announced that on February 11, 2019, the U.S. Court of Appeals for the Federal Circuit  denied Indivior’s motion to stay issuance of the mandate following ...

Indivior PLC (LON: INDV)  today announced that the U.S. Court of Appeals for the Federal Circuit (“CAFC”) has denied Indivior’s motion for rehearing and rehearing en banc following the CAFC’s ...

Indivior PLC (LON: INDV) today announced that it has entered into an agreement with Alvogen Pine Brook LLC, enjoining Alvogen from the use, offer to sell, or sale within the ...